



Webinar Faculty





Target Audience

 The overarching goal of PCSS is to train healthcare professionals in evidence-based practices for the prevention and treatment of opioid use disorders, particularly in prescribing medications, as well for the prevention and treatment of substance use disorders.

> P C S S Providers Clinical Support

5



























Considerations For Late-life Diagnosis



Late-life Risk & Protective Factors For SUDs

Risk Factors:

- Previous history of SUD (including relapse)
- Comorbid psychiatric illness
- Cognitive impairment
- Family history of SUD
- Retirement that is not voluntary
- Loss (spouse, friend)
- Worsening physical health
- Availability of substances
- Male gender
- Black and white races
- High school education or beyond
- Chronic physical illness or pain
- Being a caregiver

Protective Factors:

- Married
- Religious affiliation
- Late-life onset
- Good social support
- Resiliency
- Demonstrated ability to live independently
- Good sense of identity & purpose

Sate, D., et al., (2012), Journal of Studies on Alcohol and Dugs Substance Abuse and Mental Health Services Administration, (2019), Substance Abuse and Mental Health Services Administration Wu LT., et al., (2011), Journal of Aging Health	, D., et al., (20 ance Abuse a h Services Adi	012), <i>Journal</i> and Mental H	l of Studies lealth Servic	s on Alcohol	and Drugs		
Substance Abuse and Mental Health Services Administration, (2019), Substance Abuse and Mental Health Services Administration Wu LT., et al., (2011), Journal of Aging Health	ance Abuse a h Services Adi	ind Mental H	ealth Servic				
Wu LT., et al., (2011), Journal of Aging Health		ministration		ces Admini	stration, (2019), Substance Abu	se and Mental
	T., et al., (2011	1), Journal o	f Aging Hea	alth			
			P	PC	PCSS	PCSS Clinic	PCSS Clinical Support













Risk Factors For Alcohol Misuse In Late Life Physical: Chronic pain • Physical disabilities Change in living situation Overall poor health status Chronic physical illness • Mental: Avoidant coping style (drinking to cope) . History of alcohol misuse in past SUD in past (or currently meet criteria for other SUD) Past or current co-occurring mental illness . Social: Financial stressors Bereavement Unexpected/forced retirement Kuerbis A., et al., (2014), Clinical Geriatric Medicine Lack of social support PCSS 27

Signs & Symptoms Of Alcohol Use Disorder (AUD) In Late-life

Mental/Cognitive Changes:

- Anxiety, depression, emotional lability
- New social isolation
- Disorientation, memory loss, difficulties w/ decision-making
- Idiopathic seizures
- Physical Health:
 - Poor hygiene
 - Falls, bruises (rule out elder mistreatment)
 - Poor nutrition
 - New incontinence
 - New sleep problems

Alcohol and Medications:

- Increased alcohol tolerance (although not always seen in older adults)
- Unusual medication response



PCSS

28





Pharmacologic Treatments For Alcohol Withdrawal

- Lorazepam (Ativan)
 - PO, IM, IV forms available
 - Part of "LOT" (lorazepam-oxazepamtemazepam) group – not hepatically metabolized
 - Linear kinetics & well absorbed
- Chlordiazepoxide (Librium)
 - PO form only
 - Hepatically metabolized, has active metabolite
 - Longer half life than lorazepam, risk for "stacking"***
- ***Avoid benzodiazepine if individual is intoxicated (e.g. in situation in which individual is acutely agitated)
 P C S S Provider





31

Naltrexone Hydrochloride Tablets, USP

32

50 mg

PCSS



Naltrexone

- 50mg PO daily (**Revia**)
- 380mg IM q monthly (Vivitrol)
- Mechanism: Competitive antagonist at mu opioid receptor.
- Potential side effects: Dizziness, headaches, GI distress

• **Other**: Use w/ caution in decreased liver function; check transaminases.

- Shown to decrease relapse, increase days of before relapse and decrease heavy drinking days.
- Geriatric considerations:
 - No change from adult dosing.
 - Avoid if individual is on opioid therapy or 7-14 days after last use.
 - Avoid with acute liver failure or concern for hepatotoxicity.
 - Safe to use in compensated cirrhosis.

Ayyala D., et al., (2022), Hepatology Communication













Pharmacologic Treatments – Nicotine Replacement Therapy

- Inhaler: Nicotrol
 - Dose: 10mg
 - 6-16 cartridges daily for up to 12 weeks
 - No studies evaluating use after 12 weeks
 - Potential side effects: Sore throat, oral irritation, headache
 - Geriatric considerations:
 - Avoid in those with bronchospastic disease.

Nasal Spray: Nicotrol NS

- Dose: 10 mg/mL
- Take as 1-2 doses an hour with no more than 5 doses (10 sprays) an hour
- Not studied beyond 3 months of treatment.
- Potential side effects: Nasal discomfort, rhinitis, dyspepsia
- Geriatric considerations:
 - Avoid in chronic nasal disorders (sinusitis,
 - rhinitis) and severe reactive airway disease.

Lozenges:

- Dose: 2mg, 4mg every 1-2 hours with max of 20 lozenges a day.
- Potential side effects: Buccal mucous irritation, nicotine-related GI distress, headaches, palpitations
- Geriatric considerations:
 - Better choice in those w/ poor dentition or dentures.
- Good for breakthrough cravings/requires specific dosing for maximal results.



Pharmacologic Treatments
Varenicline (Chantix)
Dose:
Day 1-3: 0.5mg q day
Day 4-7: 0.5mg BID
Day 8 on: 1mg BID
 Mechanism: Alpha4-beta-2 nicotinic acetylcholine receptor partial agonist
 Potential side effects: Nightmares, GI upset, behavioral disturbance
Geriatric Considerations:
 No adjustments needed for older adults unless there is a history of renal impairment.
 Creatinine clearance < 30 mL/minute: Initiate with 0.5mg daily but maintenance remains 0.5mg BID.
 History of end stage renal disease: maximum dose of 0.5mg daily.
Bupropion SR Formulation (Zyban)
Mechanism: Weak inhibition of dopamine reuptake
Dose:
 Day 1-3: 150mg daily
 Day 4 on: 150mg BID
 Potential side effects: Increased anxiety, irritability (typically w/ higher doses)
Geriatric Considerations: P C S S Providers 40
 Well-tolerated in older adults.









American Geriatric Society (AGS) Beers Criteria Was updated in 2019 with the recommendation to avoid opioids for chronic pain. Use should be reserved for the management of severe acute pain. A review of opioid-related deaths from 2001-2016 found: Older adults constituted the largest relative increase during this period.

P C S S Clinical Support

45

- Age 55-64: 754% increase.
- Age > 65: 635% increase.

Fick DM., et al. (2019), Journal American Geriatric Society Gomes T., et al. (2018), JAMA Network Open



Pharmacologic Treatments -Buprenorphine (+ Naloxone) Buprenorphine + Naloxone (Suboxone) • Dose: Depends on formulation, for Suboxone film; 4mg, 8mg, 12mg • Mechanism: Partial agonist at Mu opioid receptor and

- Mechanism: Partial agonist at Mu opioid receptor and antagonist at kappa opioid receptor
- Potential side effects: Constipation, headache, trouble concentrating

Geriatric Considerations:

- Lower misuse potential than methadone (ceiling effect, naloxone presence)
- Half-life is not altered with impaired renal or hepatic function.
- As effective as methadone for moderate use d/o.
- Weak opioid effect when compared to methadone.
- Not as much known when compared to methadone.
- Other: One study of low-dose buprenorphine in older adults w/ depression found medication to be safe and well-tolerated.



Pharmacologic Treatments - Vivitrol

- Factors that influence use of Naltrexone (Vivitrol) for OUD:
 - Highly-motivated individual.
 - Recently detoxified from methadone maintenance treatment or buprenorphine maintenance.
 - Not eligible for methadone maintenance treatment or buprenorphine maintenance.
 - Individuals who do not want prescriptions to appear on PDMP.
 - Desire to avoid new dependence after being in recovery.
- Dose: 380mg injection every 28 days







Cannabis Use Disorder In Late Life

- Cannabis use changing with legalization.
- In 2013 & 2014 0.6% of those > 50yo used medical cannabis.
 - Cannabis Use Disorder Identification Test-Revised (CUDIT-R):
 - Score of 12 or higher suggests need for further evaluation.
 - Not developed specifically for older adults.
- Risks:
 - Misuse of medical cannabis
 - Diversion (with consideration of it being forced/coercion)
 - Cognitive impairment
 - Psychomotor slowing
 - Increased risk of myocardial infraction, cerebrovascular accident, psychosis and suicide.
 - Increased potency of tetrahydrocannabinol through years has increased risk of side effects.

enter for Behavioral Health Statistics and Quality. (2020), Substance Abuse and Mental Health Services Administration

ElSohly, M. A., et al., (2016), *Biological Psychiatry* Minerbi, A., et al., (2019), *Drugs and Aging*



					IT F			
			CU	D		K		
	The Cannab	is Use Disorder Ide	ntification Test -	Revised	(CUDIT-R)			
	Have you used any cann	abis over the past six month	e YES/NO					
	If YES, please answer the in relation to your cannab	following questions about yo is use over the past six months	ur cannabis use. Circle the	response that	is most correct for you			
1.	How often do you use	caratabis?						
	Never	Monthly or less	2-4 times a month	2-3 times a week	4 or more times a week			
	0	1	2	3	4			
2.	How many hours were Less than 1 0	you "stend" on a typical day 1 or 2 1	when you had been using 3 or 4 2	cannabis1 5 or 6 3	7 or more 4			
3.	How often during the p	past 6 months did you find that	you were not able to stop	using cannabi	s once you had started?			
	Never	Less than monthly	Monthly	Weekly	almost daily			
	0	1	4		*			
4.	How othern during the j	past 6 months did you sail to d	o what was normally expe Monthly	Workly	because of using cannabis? Daily or			
	0	1	2	3	almost daily 4			
5.	How often in the past	5 months have you devoted a g	reat deal of your time to g	etting, using, o	ar recovering from			
	carnabis?	Less than monthly	Monthly	Washin	Daily or			
	0	1	2	3	almost daily 4			
6.	How often in the past	5 months have you had a prob	iem with your memory or -	oncentration a	after using cannabis?			
	Never	Less than monthly	Monthly	Weekly	Daily or almost daily			
7.	0 How often do you use	l cannabis in situations that cou	2 Id be physically hazardous	, such as drivi	4 ng. operating machinery,			
	or caring for children: Never	Less than monthly	Monthly	Weekly	Daily or			
	0	1	2	3	4			
8.	Have you ever thought Never	about cutting down, or stoppi Yes	ng, your use of cannabis? , but not in the past 6 months 2		Yes, during the past 6 months			
	This ere	le is in the nublic domain -	- and is free to use with a	meaneinte «	Intion			
	Adamson SI, Kay-J see	bkin FJ. Baker AL. Lowin	II. Thornton I., Kelly B	L and Sellers	n ID (2010) An			
	Improved Brief Measur (CUDIT-R). Drug and	e of Cannabis Misuse: The Alcohol Dependence 110:1:	Cannabis Use Disorder 37-143.	Identificatio	n Test - Revised			
	This questionnaire v 8 items: - Question 1-7 are s - Question 8 is scor	was designed for self a scored on a 0-4 scale ed 0, 2 or 4.	dministration and is	acored by a	adding each of the			Descriptions
	Scoree of 8 or more	undicate hazardoite ca	name use while er	Since of 12	or more indicate a	and the second se	Contraction of the second s	CTOVIDEON N







Florida - <u>BR</u>ief Intervention and <u>Treatment for</u> <u>E</u>lders (BRITE)

- Florida Brief Intervention and Treatment for Elders Modeled on SBIRT
 - Involved older adults who screened positive for needing brief SUD intervention.
- Components:
 - Education
 - Motivational interviewing
 - Age-appropriate information: Coping mechanisms, prevention, recognizing high-risk situations.

Florida BRITE Project

56

PCSS

- Results:
 - Lower SMAST-G scores
 - Nearly 30% of participants had fewer flags for prescription misuse.
 - Large decrease in depression and suicide risk scores.

Creating A Treatment Environment Appropriate For Older Adults

Match Treatment To Individual's Needs:

- Provide services during daytime hours.
- Assist with transportation.
- In-home or telehealth services if homebound.
- Residential Treatment Program for older adults should be easy to navigate, e.g., well-lit and accessible for individuals with assistive devices.
- Accommodate for vision and hearing impairments.
- Presentations should have slower pace, frequent repetition of important information and incorporated time for participants to ask questions.
- **Age-specific topics**: grief & loss, isolation, social pressure, life-stage, role transitions.

Substance Abuse and Mental Health Services Administration (SAMHSA), (2020), Treatment Improvement Protocol Ser No 26, SAMHSA Publ No PEP20-02-01-011.

Creating A Treatment Environment Appropriate For Older Adults

- Consider how one may draw from their cultural background to improve health.
- Determine whether there is a prior history of SUD or if use occurred in response to a stressor.
- Harm reduction vs. abstinence

Substance Abuse and Mental Health Services Administration (SAMHSA), (2020), Treatm Ser No 26, SAMHSA Publ No PEP20-02-01-011.

- Person-centered care: Use individual's values/preferences in decision-making.
- Stronger therapeutic alliance leads to greater retention and engagement.



PCSSSClinical Support

57





Barriers To Identification/Diagnosis Healthcare system factors: Stereotypes about addiction & older adults. . Misattribute symptoms (e.g., falls, impaired sleep, cognitive impairment) to other causes. Lack of training in screening, interventions, treatments, and prognosis. Individual attributes symptoms to aging or does not consider use as problematic. Shame and guilt may inhibit from seeking care . Stigma with acknowledging illness and seeking care. Unaware that SUDs are treatable. . **Diagnostic Concerns:** Co-morbid medical conditions may "mask" SUD presentation (i.e., listlessness attributed to CHF exacerbation and not intoxication). Fewer overt warning signs (especially if chronic use). DSM-5-TR criteria may not fully capture an older adult's presentation. Most diagnostic criteria and screening tools for SUDs were developed and validated for younger persons. Blazer DG., et al., (2009), American Journal of Geriatric Psychiatry PCSSSClinical Support Blow FC., (2012), Current Psychiatry Reports 61 Yarnell S., et al., (2020), American Journal of Geriatric Psychiatry.



References

- Aira, M., Hartikainen, S., & Sulkava, R. (2008). Drinking alcohol for medicinal purposes by people aged over 75: A community-based interview study. Family Practice, 25(6), 445–449 Alpert PT. Alcohol abuse in older adults: An invisible population. *Home Heal Care Manag Pract.* 26(4).
- American Psychological Association, Committee on Aging. (2009). Multicultural competency in
- geropsychology. Washington, DC: American Psychological Association. Retrieved from www.apa.org/ pi/aging/programs/pipeline/multicultural-competency.pdf Ayyala D, Bottyan T, Tien C, et al. (2022) Naltrexone for alcohol use disorder: Hepatic safety in patients
- with and without liver disease. Hepatol Commun: 3433-3442. doi:10.1002/hep4.2080
- Barry, K. L., & Blow, F. C. (2016). Drinking over the lifespan: Focus on older adults. Alcohol Research, 38(1), 115-120.
- Benshoff, J. J., Harrawood, L. K., & Koch, D. S. (2003). Substance abuse and the elderly: Unique issues and concerns, Journal of Rehabilitation, 69(2), 43-48,
- Blow FC, Barry KL: Alcohol and substance misuse in older adults. Curr Psychiatr Rep 2012; 14:310-319 Breslow RA, Dong C, White A. (2015). Prevalence of alcohol-interactive prescription medication use
- among current drinkers: United States, 1999 to 2010. Alcohol Clin Exp Res.; 39(2):371-379. Briscoe J, Casarett D. (2018). Medical marijuana use in older adults. J Am Geriatr Soc.; 66:859-863. Center for Behavioral Health Statistics and Quality. (2020). Results from the 2019 National Survey on Drug
- Use and Health: Detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from www.samhsa.gov/data/ Centers for Disease Control and Prevention. (2008) Smoking and Older
- Adults. https://www2c.cdc.gov/podcasts/media/febd/Health/AgingSmoking.pdf Chait R, Fahmy S, Caceres J (2010): Cocaine abuse in older adults: an underscreened cohort. J Am Geriatr Soc.: 58:391-392





References Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. (2018), The Burden of Opioid-Related Mortality in the United States. *JAMA Netw open*.;1(2):e180217. doi:10.1001/jamanetworkopen.2018.0217 Grant BF, Chou SP, Saha TD, et al. 2017. Prevalence of 12-month alcohol use, high-risk drinking, and DSM-IV alcohol use disorder in the United States, 2001-2002 to 2012-2013: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. JAMA Psychiat.; 74(9): 911-923 Hadland, S. E., Park, T. W., & Bagley, S. M. (2018). Stigma associated with medication treatment for young adults with opioid use disorder: a case series. Addiction science & clinical practice, 13(1), 15. https://doi.org/10.1186/s13722-018-0116-2 Han B, Moore A, Ferris R, Palamar J. (2019) Binge drinking among older adults in the United States, 2015-2017. *Journal of the American Geriatrics Society*.; 67(10). <u>https://doi.org/10.1111/jgs.16071</u> Huhn AS, Strain EC, Tompkins DA, Dunn KE. (2018) A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder. Drug Alcohol Depend.; 193: 142-147. doi: 10.1016/i.drugalcdep.2018 Johnson RB. (2008) Identification and Treatment of the Geriatric Alcoholic Dental Patient. Compend Contin Educ Dent. Johnson RB. (2008) Identification and Treatment of the Geriatric Alcoholic Dental Patient. Compend Contin Educ Dent. Jonan, A.B., Kaye, A., & Urman, R. (2018). Buprenorphine Formulations: Clinical Best Practice Strategies Recommendations for Perioperative Management of Patients Undergoing Surgical or Interventional Pain Procedures. Pain physician, 21 1, E1-E12. Jones, C. M., Paulozzi, L. J., & Mack, K. A. (2014). Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths: United States, 2010. Morbidity and Mortal Weekly Report, 63(40), 881–885. Kuerbis, A., Sacco, P., Blazer, D. G., & Moore, A. A. (2014). Substance abuse among older adults. Clinics in Geriatric Medicine, 30(3), 629-654. P C S S Providers Clinical Support 65



References Sanna, M. B., Tuqan, A. T., Goldsmith, J. S., Law, M. S., Ramirez, K. D., Liao, D. H., & Moore, A. A. (2015). <u>Characteristics of older at-risk drinkers who drive after drinking and those who do not drive after drinking</u>. *Traffic injury prevention*, *16*(2), 104–108. Satre, D., Chi, F., Mertens, J., & Weisner, C. (2012). Effects of age and life transitions on alcohol and drug treatment outcome over nine years. Journal of Studies on Alcohol and Drugs, 73, 459-468. Shutte, K., Lemke, S., Moos, R. H., & Brennan, P. L. (2014). Age-sensitive psychosocial treatment for older adults with substance abuse. In I. Crome, L.-T. Wu, R. Rao, & P. Simou E, Britton J, Leonardi-Bee J. (2018) Alcohol and the risk of sleep apnea: A systemic review and metaanalysis. Sleep Med.; 30(3):629-654. Solliver JD, Compton WM, Gfroerer JC, Condon T. (2006). Projecting drug use among aging baby boomers in 2020. Ann Epidemiol.; 16:257-265. Substance Abuse and Mental Health Services Administration. (2019). Get connected: Linking older adults with resources on medication, alcohol, and mental health. HHS Publication No. (SMA) 03-3824. Rockville, MD: Substance Abuse and Mental Health Services Administration. Retrieved from https://store.samhsa.gov/product/Get- Connected-Linking-Older-Adults-with-Resources-on- Medication-Alcoholand-Mental-Health-2019-Edition/ SMA03-3824 Tannenbaum, C., Paquette, A., Hilmer, S., Holroyd- Leduc, J., & Carnahan, R. (2012). A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic, and opioid drugs. Drugs and Aging, 29(8), 639–658. Yarnell S, Li L, MacGrory B, Trevisan L, Kirwin P. (2020). Substance Use Disorders in Later Life: A Review and Synthesis of the Literature of an Emerging Public Health Concern. Am J Geriatr Psychiatry.; 28(2):226-236. doi:10.1016/j.jagp.











P C S	S Providers Clinical Support System
PCSS is a collaborative effort led b Psychiatry (AAAP) in partnership v	by the American Academy of Addiction vith:
Addiction Technology Transfer Center	American Society of Addiction Medicine
American Academy of Family Physicians	American Society for Pain Management Nursing
American Academy of Pain Medicine	Association for Multidisciplinary Education and Research in Substance use and Addiction
American Academy of Pediatrics	Council on Social Work Education
American Pharmacists Association	International Nurses Society on Addictions
American College of Emergency Physicians	National Association for Community Health Centers
American Dental Association	National Association of Social Workers
American Medical Association	National Council for Mental Wellbeing
American Osteopathic Academy of Addiction Medicine	The National Judicial College
American Psychiatric Association	Physician Assistant Education Association

